Brokers Set Expectations for UBX FY2024 Earnings

Posted by Joseph McCarthy on Jan 15th, 2025

Unity Biotechnology, Inc. (NASDAQ:UBX – Free Report) – Research analysts at Chardan Capital issued their FY2024 EPS estimates for Unity Biotechnology in a note issued to investors on Sunday, January 12th. Chardan Capital analyst D. Gataulin forecasts that the company will post earnings of ($1.41) per share for the year. Chardan Capital currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($1.49) per share. Chardan Capital also issued estimates for Unity Biotechnology’s FY2025 earnings at ($0.74) EPS.

Unity Biotechnology Stock Down 0.6 %

UBX stock opened at $1.71 on Wednesday. The stock has a market capitalization of $28.81 million, a price-to-earnings ratio of -1.31 and a beta of 0.80. Unity Biotechnology has a 52-week low of $0.94 and a 52-week high of $2.02. The stock’s fifty day simple moving average is $1.19 and its 200-day simple moving average is $1.36.

Unity Biotechnology (NASDAQ:UBX – Get Free Report) last released its earnings results on Monday, November 4th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.02.

Institutional Trading of Unity Biotechnology

An institutional investor recently raised its position in Unity Biotechnology stock. Geode Capital Management LLC increased its stake in Unity Biotechnology, Inc. (NASDAQ:UBX – Free Report) by 9.5% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 163,242 shares of the company’s stock after acquiring an additional 14,199 shares during the period. Geode Capital Management LLC owned approximately 0.97% of Unity Biotechnology worth $240,000 as of its most recent SEC filing. 29.49% of the stock is owned by institutional investors.

Unity Biotechnology Company Profile

(Get Free Report)

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.